Neurology - Clinical Trials Daily

Neurology

SKY-0515 Demonstrates First-in-Class Restorative Potential in Huntington's Disease, Establishing New Standard of Care Trajectory

Phase 1 interim data suggests a restorative signal (+0.64 cUHDRS) distinct from competitor stabilization, driven by deep target engagement and somatic expansion inhibition. See Disclaimer below * Unmet Medical Need Huntington’s Disease (HD) remains a fatal, autosomally dominant neurodegenerative disorder with no approved disease-modifying therapies (DMTs). The current prevalence

Neurology

Assessing the Clinical Viability of Intrathecal NaV1.1 Upregulation in Dravet Syndrome: The Transformational Potential and Operational Risks of Zorevunersen (STK-001)

Explore the clinical potential of Zorevunersen (STK-001) for Dravet Syndrome. Learn how NaV1.1 upregulation targets SCN1A haploinsufficiency to modify disease.

Neurology

NMRA-511 as a Precision Therapeutic for Anxiety-Driven AD Agitation

Addressing the critical gap in agitation management through non-sedating V1a antagonism and phenotype-selective development. See Disclaimer below * Alzheimer’s Disease (AD) affects an estimated 6.7 million Americans, with agitation and aggression emerging in approximately 40-50% of patients during the disease course. This translates to a Total Addressable Market (TAM)

Neurology

ACI-7104.056 Parkinson’s "Vaccine": Interim VacSYn Data Challenges the "Symptomatic Only" Treatment Paradigm

AC Immune’s Phase 2 interim analysis delivers a rare trifecta in neurodegeneration: 100% target engagement, biomarker stabilization, and clinical efficacy signals. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * In a therapeutic

Neurology

TRPM8 Validation: Elismetrep Shows Promise in Phase 2b for Acute Migraine Without Thermoregulation Liability

Kallyope's first-in-class oral antagonist meets co-primary endpoints, offering a distinct non-CGRP mechanism for refractory patients. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Impact Analysis The landscape of acute migraine

News

Deramiocel Achieves Statistical Significance in Phase 3 HOPE-3 Trial: 54% Slowing of Skeletal Disease Progression and Critical Cardiac Preservation

Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.

News

CervoMed’s Neflamapimod Reduces Plasma GFAP by 16% in DLB, Validating 'Bioavailability Hypothesis' for Phase 3

New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.